

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

APPOINTMENT OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”) is pleased to announce that Ms. Leah Liu (劉栩昕) (“**Ms. Liu**”) has been appointed as the joint company secretary of the Company with effect from 28 March 2022.

After the aforesaid appointment, the existing company secretary of the Company, Ms. Lau Yee Wa (劉綺華) will continue to serve as the other joint company secretary.

The biographical details of Ms. Liu are set out below:

Ms. Liu joined the Company in October 2021 and is the vice president of corporate affairs of the Company, responsible for overseeing the compliance affairs in relations to capital markets, public relations, board of directors, and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”). Prior to joining the Company, Ms. Liu was chief financial officer of Laekna Therapeutics and head of capital markets at I-Mab (NASDAQ: IMAB) where she led financing and capital markets efforts, including listing preparations. Ms. Liu also worked in CloudMinds Technology (Hong Kong) Limited and Xtep International Holdings Limited (HKEX: 1368) as the head of capital markets and director of investor relations respectively and was the recipient of multiple industry awards. Ms. Liu has extensive experience in the financial services and investment industries and held positions at major international investment banks including The Hongkong and Shanghai Banking Corporation Limited, Daiwa Capital Markets Hong Kong Limited and Lazard Ltd.

Ms. Liu received double bachelor’s degrees in biology and international studies and a master’s degree in cellular molecular biology from The Johns Hopkins University. Ms. Liu also received a master’s degree in corporate governance from Hong Kong Metropolitan University (formerly known as The Open University of Hong Kong) in 2020. Ms. Liu is an associate member of each of The Hong Kong Chartered Governance Institute (formerly known as The Hong Kong Institute of Chartered Secretaries) and The Chartered Governance Institute (formerly known as The Institute of Chartered Secretaries and Administrators) in the United Kingdom.

The Board would like to take this opportunity to express its warmest welcome to Ms. Liu on her new appointment.

By Order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 28 March 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.